

Special Issue

Management of Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer represents a highly lethal disease and an increasingly common cause of cancer mortality worldwide. Despite significant achievements in molecular biology, diagnosis, and multi-modal treatment options, most patients are diagnosed with pancreatic cancer at advanced stages, when curative treatment is impossible. Although surgery represents the single hope for long-term survival in patients diagnosed with resectable pancreatic cancer, resection usually implies complex surgical procedures with high morbidity, non-neglectable mortality rates, and disappointing long-term survival. Furthermore, for locally advanced and metastatic pancreatic cancer, the prognosis is even worse. Therefore, identifying new therapeutical options and an early diagnosis appear to be critical for maximizing therapeutic efficacy and avoiding unnecessary aggressive therapies in pancreatic cancer. We look forward to your submissions to the Special Issue project.

Guest Editor

Dr. Traian Dumitrascu

Center of General Surgery and Liver Transplantation, Fundeni Clinical Institute, 022328 Bucharest, Romania

Deadline for manuscript submissions

31 October 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/168457

Cancers

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)